Heart failure treatment up‐titration and outcome and age: an analysis of BIOSTAT‐CHF,European Journal of Heart Failure

当前位置： X-MOL 学术 › Eur. J. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Heart failure treatment up‐titration and outcome and age: an analysis of BIOSTAT‐CHF
European Journal of Heart Failure ( IF 18.2 ) Pub Date : 2020-03-25 , DOI: 10.1002/ejhf.1799
Ify R Mordi ₁ , Wouter Ouwerkerk _{2,

3} , Stefan D Anker ₄ , John G Cleland ₅ , Kenneth Dickstein _{6,

7} , Marco Metra ₈ , Leong L Ng ₉ , Nilesh J Samani ₉ , Dirk J van Veldhuisen ₁₀ , Faiez Zannad ₁₁ , Adriaan A Voors ₁₀ , Chim C Lang ₁

Affiliation

Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.
National Heart Centre Singapore, Singapore.
Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, The Netherlands.
Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Berlin, Germany.
National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, London, UK.
University of Bergen, Bergen, Norway.
Stavanger University Hospital, Stavanger, Norway.
Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK.
University Medical Center Groningen, Department of Cardiology, University of Groningen, Groningen, The Netherlands.
Inserm CIC-P 1433, Université de Lorraine, CHRU de Nancy, FCRIN INI-CRCT, Nancy, France.

Several studies have shown that older patients with heart failure with reduced ejection fraction (HFrEF) are undertreated. The aim of this study was to evaluate the association of up‐titration of angiotensin‐converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) and beta‐blockers on outcome across the age spectrum in HFrEF patients.

中文翻译：